PORTLAND, Ore., Aug. 4, 2025 /PRNewswire/ — Skypoint, the trusted leader in unified data and agentic AI solutions for healthcare, today announced the launch of its fully AI-powered Agentic Apps designed specifically for Prior Authorization (PA) and Referral Management. With healthcare providers facing critical staffing shortages and increasing administrative workloads, Skypoint’s innovative solution addresses these pain points by automating and orchestrating the complete PA and referral lifecycle.
Unlike tools that merely digitize manual processes, Skypoint’s Agentic Apps embed responsible, context-aware intelligence directly into clinical workflows. These advanced AI capabilities help healthcare providers significantly reduce administrative burden, delivering measurable outcomes and creating 30% additional capacity for direct patient care.
“Every missed referral or authorization represents a lost opportunity for patient care,” said Tisson Mathew, Skypoint’s CEO. “Our AI-driven apps ensure nothing falls through the cracks, enabling seamless tracking, immediate follow-ups, and unprecedented transparency. We know providers work across EHRs, faxes, handwritten notes, and evolving payer rules. Skypoint adapts to your world, integrating directly with major EHRs and processing documents like faxes and handwritten forms.”
Key differentiators of Skypoint’s Agentic Apps include:
Healthcare organizations already utilizing Skypoint’s AI-Powered Agentic Apps have reported substantial operational improvements, including:
Skypoint’s commitment to radical transparency ensures AI processes are clear, auditable, and explainable, supporting responsible and trusted AI adoption within healthcare organizations.
Healthcare leaders interested in seeing how Skypoint can transform their PA and referral workflows are encouraged to schedule a personalized demonstration. To request a demo of Skypoint’s AI Agents for Prior Authorization or Referral Management, contact sales@skypoint.ai today.
SOURCE Skypoint
SEATTLE, WA / ACCESS Newswire / December 26, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a…
While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn…
DALLAS, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and…
This Christmas season, President Trump's executive action to advance rescheduling and medical research has finally…
KANAZAWA, Japan, Dec. 26, 2025 /PRNewswire/ -- Scientists at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa…
LOS ANGELES, Dec. 25, 2025 /PRNewswire/ -- From January 6–9, 2026, visitors can experience Arspura's…